Pei Hu

chinese academy of medical sciences & peking union medical college; beijing key laboratory of clinical pk & pd investigation for innovative drugs

H指数:28

被引数:3,235

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical trial on the pharmacokinetics; pharmacodynamics and safety of tolvaptan in healthy Chinese males: an open-label; single and multiple dosage; parallel group study

关于托伐普坦在健康中国男性中的药代动力学、药效学和安全性临床研究：一项开放标签、单次与多次剂量、平行组研究

Frontiers in Pharmacology

IF4.8

2025-11-210

OAAI

A meta-analysis of the effect of computerized cognitive training on cognitive function in patients with Multiple Sclerosis

计算机化认知训练对多发性硬化患者认知功能影响的meta分析

Multiple Sclerosis and Related Disorders

IF2.9

2025-09-250

PRE

The CYP2D6 phenotyping performance of single-point saliva metabolic ratio in a healthy Chinese Han population

单点唾液代谢率在中国汉族健康人群中的CYP2D6表型分析性能

FRONTIERS IN PHARMACOLOGY

IF4.8

2025-02-210

Constructing two bifunctional tooth-targeting antimicrobial peptides for caries management: an in vitro study

CLINICAL ORAL INVESTIGATIONS

IF3.1

2024-12-310

PRE

Structure Elucidation and Immunostimulatory Activity Evaluation of a Galactoglucan from Alpinia officinarum Hance

结构解析及一种来自Alpinia officinarum Hance的半乳葡聚糖的免疫刺激活性评价

FOODS

IF5.1

2024-12-120

Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study

hematology oncology

IF13.5

2024-06-121

OAAI

Comment on 'effects of multicomponent exercise on the muscle strength, muscle endurance and balance of frail older adults: A meta-analysis of randomised controlled trials'

JOURNAL OF CLINICAL NURSING

IF3.5

2024-04-250

PRE

Synthesis and Neuroprotective Evaluation of Substituted Indanone/Benzofuranone and Piperidine Hybrids

ACS CHEMICAL NEUROSCIENCE

IF3.9

2024-04-242

PRE

LATS1/YAP1 Axis Controls Bone Regeneration on Distraction Osteogenesis by Activating Wnt/β-Catenin

TISSUE ENGINEERING PART A

IF2.9

2024-02-014

PRE

Hypermethylated CDO1 and CELF4 in cytological specimens as triage strategy biomarkers in endometrial malignant lesions

FRONTIERS IN ONCOLOGY

IF3.3

2023-12-013

OAAI

Safety, tolerability, pharmacokinetics, and efficacy of kukoamine B in patients with sepsis: A randomized phase IIa trial

kukoamine B在脓毒症患者中的安全性，耐受性，药代动力学和有效性: 一项随机IIa期试验

JOURNAL OF CRITICAL CARE

IF2.9

2023-08-010

PRE

Safety, Tolerability, and Pharmacokinetics of Kukoamine B in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Phase I Study

Kukoamine B在健康志愿者中的安全性，耐受性和药代动力学: 一项随机，双盲，安慰剂对照，多剂量I期研究

ADVANCES IN THERAPY

IF4

2023-05-262

OAAI

Pharmacokinetic characteristics of golidocitinib, a highly selective JAK1 inhibitor, in healthy adult participants

FRONTIERS IN IMMUNOLOGY

IF5.9

2023-04-035

OAAI

A model-based meta analysis study of sodium glucose co-transporter-2 inhibitors

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2023-03-084

OAAI

Safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of WBP216, a novel IL-6 monoclonal antibody, in patients with rheumatoid arthritis: A phase Ia randomized placebo-controlled study

FRONTIERS IN IMMUNOLOGY

IF5.9

2023-02-281

OAAI

Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study

BMC MEDICINE

IF8.3

2022-11-2312

OAAI

Safety, pharmacokinetics, and efficacy of BPI-15086 in patients with EGFR T790M-mutated advanced non-small-cell lung cancer: results from a phase I, single-arm, multicenter study

ESMO OPEN

IF8.3

2022-06-010

OAAI

Fixed dosing of kukoamine B in sepsis patients: Results from population pharmacokinetic modelling and simulation

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2022-04-233

OAAI

Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial (vol 12, 779365, 2021)

FRONTIERS IN ENDOCRINOLOGY

IF4.6

2021-12-280

OAAI

Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population

JOURNAL OF DIABETES INVESTIGATION

IF3

2021-12-283

Pei Hu

个人简介

教育背景

工作经历

荣誉奖项

研究方向